San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, Neurelis is raising $15,348,001.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Craig Chambliss played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Neurelis

Neurelis, Inc. is a privately-held San Diego-based specialty pharmaceutical company devoted to developing treatment options for epilepsy, while also investigating new treatment options for the unmet needs of central nervous system (CNS) disorders.

To learn more about Neurelis, visit http://www.neurelis.com/

Contact:
Craig Chambliss, Chief Executive Officer
858-531-5859
cchambliss@neurelis.com
https://www.linkedin.com/in/craigchambliss/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved